Replies to post #76824 on Anavex Life Sciences Corp (AVXL)

[makemydaze]

Biogen had 2 phase 2 trials running for Opicinumab. The trial regarding MS failed to meet its endpoint -

"Today Biogen (NASDAQ: BIIB) reported top-line results from the Phase 2 SYNERGY study evaluating opicinumab (anti-LINGO-1), an investigational, fully human monoclonal antibody being developed as a potential neuroreparative therapy in people with relapsing forms of multiple sclerosis (RMS). In the study, opicinumab missed the primary endpoint, a multicomponent measure evaluating improvement of physical function, cognitive function, and disability."

I believe the other trial codenamed "RENEW" is still alive.

http://media.biogen.com/press-release/investor-relations/biogen-reports-top-line-results-phase-2-study-opicinumab-anti-lingo

The failure in the SYNERGY trial might have accelerated BIIB's interest in 2-73.

"Biogen witnessed a fall of about 12.7% in its share price as its stock closed at $252.86 after the release of the trial results. This underlined the expectations of the investor community related to the contribution of the anti-LINGO research program to Biogen’s future growth."

[frrol]

Opicinumab just finished two Phase 2's and the results were disappointing but had hints of some effect.

Neuroinflammation is theorized to be part of many CNS pathologies and MS is no exception. I think what is happening is that 2-73 is going to be thrown at everything to see if something sticks. Soooo many variables though: dosing, disease stage, agent combos, etc. Shots in the dark.